Connect with us

Hi, what are you looking for?

Jewish Business News


Israel’s BioLight Announces Closing of Upsized $6.6 Million Private Placement

BioLight also announced that a new private investor participated in the private placement with the same terms in the amount of $350, 000.


Israel’s BioLight Life Sciences Investments Ltd., a manages and commercializes biomedical innovations in ophthalmology and cancer diagnostics, has completed an upsized private placement as part of the strategic partnership with Rock-One International Holdings Ltd for aggregate gross proceeds of $6.6 million.

The strategic partnership along with the private placement was previously announced on April 2, 2015. The offering resulted in the issuance of ordinary shares to Rock-One, which account for approximately 19% of BioLight’s issued and outstanding shares. Rock-One’s equity investment is approximately $6.25 million, a 12% premium over the average closing price of BioLight shares in the 30-days prior to signing the investment agreement.

BioLight also announced that a new private investor participated in the private placement with the same terms in the amount of $350, 000.

Leading key investors, holding about 36% of BioLight’s issued and outstanding shares, are Mr. Israel Makov, Chairman of Sun Pharmaceuticals, former CEO and President of Teva Pharmaceuticals and former Chairman of Given Imaging, Mr. Dilip Shanghvi, founder of Sun pharmaceuticals, India’s largest pharmaceutical company, and Mr. Dan Oren, founder and CEO of Dexcel Pharma, the second-largest pharmaceutical manufacturer in Israel.

Rock-One is a Hong Kong corporation with offices in Hong Kong and Macau. The company is involved with different investments in Greater China and North America, including real-estate development and construction, internet technology, agriculture, healthcare and bio-med. Patrick Lau is the founder and CEO of Rock-One.

Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.



You May Also Like

World News

In the 15th Nov 2015 edition of Israel’s good news, the highlights include:   ·         A new Israeli treatment brings hope to relapsed leukemia...


The contract signed between the Israeli government and Pfizer shows clearly and unequivocally that this is a clinical study on humans - The agreement...


Now Platika joins and elite club of $10 billion plus Israeli firms.


After two decades without a rating system in Israel, at the end of 2012 an international tender for hotel rating was published.  Invited to place bids...